Ketamine's Efficacy in Older Adults with TRD Analyzed

Ketamine's Promise for Older Adults with TRD

Treatment-resistant depression (TRD) in older adults presents unique clinical challenges due to limited efficacy of traditional antidepressants and increased susceptibility to adverse effects. A recent systematic review and meta-analysis, published in May 2026, has provided compelling evidence supporting the efficacy of ketamine and esketamine in this demographic. The analysis included thirteen primary studies conducted between 2023 and 2025, focusing on individuals aged 65 and older.

The review found that both ketamine and esketamine produced significant reductions in depressive symptoms, with a standardized mean change (SMC) of −1.68 (95% CI −1.85 to −1.51). This suggests a large and clinically meaningful impact. Importantly, the substances were generally well tolerated, with a discontinuation rate due to adverse events at a relatively low 16%.

Mechanisms and Context

Ketamine and its derivative, esketamine, are known for their rapid-acting antidepressant effects, which differ from traditional treatments that often take weeks to show benefits. These substances act on the brain's glutamate system, which may explain their ability to quickly alleviate depressive symptoms. This mechanism is particularly beneficial for older adults who may not respond well to conventional therapies.

Despite their potential, the use of ketamine and esketamine in geriatric psychiatry is still in its early stages. The meta-analysis highlights the need for further research to optimize dosing and assess long-term safety and efficacy in older populations.

Implications for Clinical Guidelines

The findings from this review could significantly influence clinical guidelines for managing TRD in older adults. As the population ages, the prevalence of depression in older adults is expected to rise, making effective treatment options crucial. Ketamine and esketamine could offer a viable alternative to conventional antidepressants, particularly for those who have not responded to other treatments.

However, the review also emphasizes the necessity for geriatric-focused trials to refine treatment protocols. Such research would help clinicians make informed decisions regarding the use of these substances in older patients, ensuring both efficacy and safety.

Risks and Unknowns

While the results are promising, there are still risks and unknowns associated with the use of ketamine and esketamine in older adults. Approximately 47% of participants in the reviewed studies experienced at least one adverse event, although most were mild. The long-term effects of these substances remain unclear, necessitating ongoing monitoring and research.

Additionally, the risk of bias varied across the studies included in the meta-analysis. Although randomized trials showed a consistently low risk of bias, further high-quality studies are needed to confirm these findings and address any potential gaps in the current research.

Future Directions

Looking forward, the need for comprehensive, geriatric-focused research is evident. Such studies should aim to refine dosing strategies, monitor long-term outcomes, and explore the broader implications of ketamine and esketamine use in older adults. This research will be crucial in guiding clinical decision-making and ensuring that these treatments are both effective and safe for this vulnerable population.

As the field of psychedelic research continues to evolve, the potential for ketamine and esketamine to transform the treatment landscape for older adults with TRD is significant. However, careful consideration of the risks and ongoing research will be essential to fully realize their benefits.